Shijie Zhou1,2, Eric Sung1,2, Adityo Prakosa1,2, Konstantinos N Aronis3,2, Jonathan Chrispin3,2, Harikrishna Tandri3,2, Amir AbdelWahab4, B Milan Horáček5, John L Sapp4, Natalia A Trayanova1,2. 1. Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA. 2. Alliance for Cardiovascular Diagnostic and Treatment Innovation, Johns Hopkins University, Baltimore, Maryland, USA. 3. Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA. 4. Department of Medicine, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada. 5. School of Biomedical Engineering, Dalhousie University, Halifax, Nova Scotia, Canada.
Abstract
INTRODUCTION: We recently developed two noninvasive methodologies to help guide VT ablation: population-derived automated VT exit localization (PAVEL) and virtual-heart arrhythmia ablation targeting (VAAT). We hypothesized that while very different in their nature, limitations, and type of ablation targets (substrate-based vs. clinical VT), the image-based VAAT and the ECG-based PAVEL technologies would be spatially concordant in their predictions. OBJECTIVE: The objective is to test this hypothesis in ischemic cardiomyopathy patients in a retrospective feasibility study. METHODS: Four post-infarct patients who underwent LV VT ablation and had pre-procedural LGE-CMRs were enrolled. Virtual hearts with patient-specific scar and border zone identified potential VTs and ablation targets. Patient-specific PAVEL based on a population-derived statistical method localized VT exit sites onto a patient-specific 238-triangle LV endocardial surface. RESULTS: Ten induced VTs were analyzed and 9-exit sites were localized by PAVEL onto the patient-specific LV endocardial surface. All nine predicted VT exit sites were in the scar border zone defined by voltage mapping and spatially correlated with successful clinical lesions. There were 2.3 ± 1.9 VTs per patient in the models. All five VAAT lesions fell within regions ablated clinically. VAAT targets correlated well with 6 PAVEL-predicted VT exit sites. The distance between the center of the predicted VT-exit-site triangle and nearest corresponding VAAT ablation lesion was 10.7 ± 7.3 mm. CONCLUSIONS: VAAT targets are concordant with the patient-specific PAVEL-predicted VT exit sites. These findings support investigation into combining these two complementary technologies as a noninvasive, clinical tool for targeting clinically induced VTs and regions likely to harbor potential VTs.
INTRODUCTION: We recently developed two noninvasive methodologies to help guide VT ablation: population-derived automated VT exit localization (PAVEL) and virtual-heart arrhythmia ablation targeting (VAAT). We hypothesized that while very different in their nature, limitations, and type of ablation targets (substrate-based vs. clinical VT), the image-based VAAT and the ECG-based PAVEL technologies would be spatially concordant in their predictions. OBJECTIVE: The objective is to test this hypothesis in ischemic cardiomyopathy patients in a retrospective feasibility study. METHODS: Four post-infarct patients who underwent LV VT ablation and had pre-procedural LGE-CMRs were enrolled. Virtual hearts with patient-specific scar and border zone identified potential VTs and ablation targets. Patient-specific PAVEL based on a population-derived statistical method localized VT exit sites onto a patient-specific 238-triangle LV endocardial surface. RESULTS: Ten induced VTs were analyzed and 9-exit sites were localized by PAVEL onto the patient-specific LV endocardial surface. All nine predicted VT exit sites were in the scar border zone defined by voltage mapping and spatially correlated with successful clinical lesions. There were 2.3 ± 1.9 VTs per patient in the models. All five VAAT lesions fell within regions ablated clinically. VAAT targets correlated well with 6 PAVEL-predicted VT exit sites. The distance between the center of the predicted VT-exit-site triangle and nearest corresponding VAAT ablation lesion was 10.7 ± 7.3 mm. CONCLUSIONS: VAAT targets are concordant with the patient-specific PAVEL-predicted VT exit sites. These findings support investigation into combining these two complementary technologies as a noninvasive, clinical tool for targeting clinically induced VTs and regions likely to harbor potential VTs.
Authors: Roderick Tung; Michael Raiman; Hongtao Liao; Xianzhang Zhan; Fa Po Chung; Rich Nagel; Hongde Hu; Jiang Jian; Dalise Y Shatz; Stephanie A Besser; Zaid A Aziz; Andrew D Beaser; Gaurav A Upadhyay; Hemal M Nayak; Takuro Nishimura; Yumei Xue; Shulin Wu Journal: J Am Coll Cardiol Date: 2020-03-03 Impact factor: 24.094
Authors: William G Stevenson; Usha B Tedrow; Vivek Reddy; Amir AbdelWahab; Srinivas Dukkipati; Roy M John; Akira Fujii; Benjamin Schaeffer; Shinichi Tanigawa; Ihab Elsokkari; Jacob Koruth; Tomofumi Nakamura; Aditi Naniwadekar; Daniele Ghidoli; Christine Pellegrini; John L Sapp Journal: J Am Coll Cardiol Date: 2019-04-02 Impact factor: 24.094
Authors: J G Kemmelings; A C Linnenbank; S L Muilwijk; A SippensGroenewegen; A Peper; C A Grimbergen Journal: IEEE Trans Biomed Eng Date: 1994-09 Impact factor: 4.538
Authors: Phillip S Cuculich; Matthew R Schill; Rojano Kashani; Sasa Mutic; Adam Lang; Daniel Cooper; Mitchell Faddis; Marye Gleva; Amit Noheria; Timothy W Smith; Dennis Hallahan; Yoram Rudy; Clifford G Robinson Journal: N Engl J Med Date: 2017-12-14 Impact factor: 91.245
Authors: K Soejima; M Suzuki; W H Maisel; C B Brunckhorst; E Delacretaz; L Blier; S Tung; H Khan; W G Stevenson Journal: Circulation Date: 2001-08-07 Impact factor: 29.690
Authors: John L Sapp; Meir Bar-Tal; Adam J Howes; Jonathan E Toma; Ahmed El-Damaty; James W Warren; Paul J MacInnis; Shijie Zhou; B Milan Horáček Journal: JACC Clin Electrophysiol Date: 2017-07-17
Authors: Adityo Prakosa; Hermenegild J Arevalo; Dongdong Deng; Patrick M Boyle; Plamen P Nikolov; Hiroshi Ashikaga; Joshua J E Blauer; Elyar Ghafoori; Carolyn J Park; Robert C Blake; Frederick T Han; Rob S MacLeod; Henry R Halperin; David J Callans; Ravi Ranjan; Jonathan Chrispin; Saman Nazarian; Natalia A Trayanova Journal: Nat Biomed Eng Date: 2018-09-03 Impact factor: 25.671
Authors: Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld Journal: Heart Rhythm Date: 2019-05-10 Impact factor: 6.343